Advances in biomarkers of myocardial injury in sepsis.
10.3760/cma.j.issn.2095-4352.2018.07.017
- Author:
Junhai ZHEN
1
,
2
;
Li LI
;
Jing YAN
Author Information
1. Department of Second Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou 310053, Zhejiang, China (Zhen JH)
2. Department of Intensive Care Unit, Zhejiang Hospital, Hangzhou 310013, Zhejiang, China (Li L, Yan J). Corresponding author: Yan Jing, Email: yanjing2013@163.com.
- Publication Type:Review
- MeSH:
Biomarkers;
Creatine Kinase, MB Form;
Humans;
Myocardial Infarction;
Myoglobin;
Natriuretic Peptide, Brain;
Sepsis;
Troponin I
- From:
Chinese Critical Care Medicine
2018;30(7):699-702
- CountryChina
- Language:Chinese
-
Abstract:
Sepsis is a common disease in critical patients, which may lead to myocardial damage, thereby aggravating the severity of the patients' condition, and causing adverse prognosis. How to detect sepsis with myocardial injury as early as possible, and use corresponding treatment measures on time are essential. Cardiac troponin I (cTnI), brain natriuretic peptide (BNP), myoglobin (Mb), MB isoenzyme of creatine kinase (CK-MB) and other traditional cardiac markers are easily affected by the complications of other critical diseases, thus the diagnostic value of those markers for myocardial injury of sepsis is reduced. In recent years, there have been some studies on heart-type fatty acid binding protein (H-FABP), microRNA (miRNA), soluble triggering receptor expressed on myeloid cell-1 (sTREM-1), high mobility group protein B1 (HMGB1), neutrophil gelatinase-associated lipocalin (NGAL), histone and other new biomarkers of myocardial injury in septic patients. This article reviewed the value of these unconventional cardiac markers in the diagnosis of sepsis-induced myocardial injury, with the hope to provide some help for clinic.
